Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Naturland Holding ZrtBUD:NATURLAND 61 EV-to-EBITDA is 20.74 as of Jul. 13, 2026, which is 3% above its 10-year median of 20.14. GuruFocus rates BUD:NATURLAND with a GF Score™ of 61/100 and a GF Value™ of Ft2,889.79 (Fairly Valued). The stock has 5 warning signs investors should review. Among 739 Drug Manufacturers companies, Naturland Holding Zrt ranks worse than 68.61% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Naturland Holding Zrt's enterprise value is Ft37,701 Mil.
Naturland Holding Zrt's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was Ft1,818 Mil. Therefore, Naturland Holding Zrt's EV-to-EBITDA for today is 20.74.
The historical rank and industry rank for Naturland Holding Zrt's EV-to-EBITDA or its related term are showing as below:
BUD:NATURLAND'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.08 Med: 20.14 Max: 35.61
Current: 20.74
During the past 5 years, the highest EV-to-EBITDA of Naturland Holding Zrt was 35.61. The lowest was 10.08. And the median was 20.14.
BUD:NATURLAND's EV-to-EBITDA is ranked worse than 68.61% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.96
vs BUD:NATURLAND: 20.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Naturland Holding Zrt's PE Ratio (TTM) for today is calculated as:
Naturland Holding Zrt's share price for today is Ft2740.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturland Holding Zrt's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was Ft105.925.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Naturland Holding Zrt EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Naturland Holding Zrt's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NATURLAND vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's EV-to-EBITDA falls into.
Naturland Holding Zrt's current Enterprise Value is Ft37,701 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturland Holding Zrt's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was Ft1,818 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naturland Holding Zrt (BUD:NATURLAND) has a EV-to-EBITDA of 20.74 as of Jul. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Naturland Holding Zrt. This is near median its historical median of 20.14. Over the past decade, Naturland Holding Zrt's EV-to-EBITDA has ranged from 10.08 to 35.61. According to the industry distribution chart, Naturland Holding Zrt ranks #507 out of 739 companies in the Drug Manufacturers industry, placing it in the top 68.6%.
Is Naturland Holding Zrt's EV-to-EBITDA too high?
Naturland Holding Zrt's current EV-to-EBITDA of 20.74 is near median its 10-year median of 20.14. Over the past 10 years, this metric has ranged from a low of 10.08 to a high of 35.61. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Naturland Holding Zrt's value of 20.74 is 60% above this industry median. Based on the distribution chart, Naturland Holding Zrt ranks #507 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Naturland Holding Zrt ranks #507 out of 739 companies for EV-to-EBITDA. This places Naturland Holding Zrt in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. Naturland Holding Zrt's value of 20.74 is 60% above this benchmark. Historically, Naturland Holding Zrt's own EV-to-EBITDA has ranged from 10.08 to 35.61 over the past decade. While the company's 10-year median is 20.14 vs. the industry median of 12.96, Naturland Holding Zrt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current EV-to-EBITDA of 20.74 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Naturland Holding Zrt. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current EV-to-EBITDA is 20.74, which is near median its own 10-year median of 20.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,889.79, compared to a current price of Ft2,740.00 — trading 5.2% below its estimated fair value. The current EV-to-EBITDA is 20.74, which is near median its 10-year median of 20.14 and 60% above the Drug Manufacturers industry median of 12.96. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current EV-to-EBITDA is 20.74 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,740.00 is trading 5.2% below its estimated GF Value™ of Ft2,889.79.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
EV-to-EBITDA: 20.74 (near median its 10-year median of 20.14)
GF Value™: Ft2,889.79 vs. price of Ft2,740.00 (5.2% below fair value)
Industry Position: 60% above the Drug Manufacturers median (#507 of 739)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
